Fabrice Lainé

Fabrice Lainé

Auto-generated profile, based on publicly available information

Fabrice Lainé

INSERM CIC 1414, Rennes, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
LFLudivine Falize
Ludivine Falize
AGAnne Guillygomarc'H
Anne Guillygomarc'H
MPMichele Perrin
Michele Perrin
FLFabrice Lainé
Fabrice Lainé
DGDominique Guyader
Dominique Guyader
YDYves Deugnier
Yves Deugnier
The current study was undertaken to assess whether fibrosis could regress under venesection therapy in patients with C282Y homozygous genetic hemochromatosis. The 36 patients studied were recruited from a subfile of our database consisting of 125 C282Y homozygotes with either severe fibrosis or cirrhosis (F3 or F4 fibrosis stage, respectively, according to the METAVIR grading system). The second liver biopsy was performed for management of liver cancer, extrahepatic surgery, or assessment of liver fibrosis. All paired biopsies were reviewed by two pathologists without knowledge of clinical data. Among the 13 patients who had F3 fibrosis on their initial liver biopsy, 3 had F0, 6 had F1, and 2 had F2 on their second liver biopsy. Among the 23 patients with cirrhosis on their initial liver biopsy, 1 had F0, 4 had F1, 3 had F2, and 2 had F3 on their second liver biopsy. When defining regression of fibrosis as a decrease of at least 2 METAVIR units, fibrosis regressed in 9 of 13 (69%) F3 and in 8 of 23 (35%) F4. When the ratio of gammaglobulins (g/L) to (platelets [n/mm3] × prothrombin activity [%]) was greater than 7.5, fibrosis never regressed. In conclusion , these data extend the concept of regression of fibrosis to patients with treated genetic hemochromatosis and suggest that some simple biochemical tests would be predictive of further regression of fibrosis as a result of venesection therapy. If confirmed on larger series, this could modify the ultrasound screening policy of hepatocellular carcinoma in genetic hemochromatosis.

1 January 2002 in Journal of Hepatology
Verified
Journal Article
Closed access
BVBartholomeus Johannes Veldt
Bartholomeus Johannes Veldt
FLFabrice Lainé
Fabrice Lainé
AGAnne Guillygomarc'H
Anne Guillygomarc'H
LLLaurence Lauvin
Laurence Lauvin
KBKarim Boudjema
Karim Boudjema
RMRomain Moirand
Romain Moirand

1 June 2005 in Blood
Verified
Journal Article
Closed access
PDF file
CLCaroline Le Lan
Caroline Le Lan
OLOlivier Loréal
Olivier Loréal
TCTally Cohen
Tally Cohen
MRMartine Ropert
Martine Ropert
HGHava Glickstein
Hava Glickstein
PBPierre Brissot
Pierre Brissot
Labile plasma iron (LPI) represents the redox active component of non–transferrin-bound iron (NTBI). Its presence in thalassemic patients has been recently reported. The aim of the present study was to quantify LPI in HFE genetic hemochromatosis (GH) and to characterize the mechanisms accounting for its appearance. We studied 159 subjects subdivided into the following groups: (1) 23 with iron overloaded GH; (2) 14 with iron-depleted GH; (3) 26 with dysmetabolic hepatosiderosis; (4) 33 with alcoholic cirrhosis; (5) 63 healthy controls. Both NTBI and LPI were substantially higher in patients with iron-overloaded GH than in those with iron-depleted GH or in healthy controls. LPI was significantly correlated with serum transaminase increase in this group. LPI was elevated in the alcoholic cirrhosis subgroup of severely affected patients. LPI was found essentially when transferrin saturation exceeded 75%, regardless of the etiologic condition. Transferrin saturation above 75% was related to iron overload in GH and to liver failure in alcoholic cirrhosis. LPI is present in C282Y/C282Y hemochromatosis and may be a marker of toxicity due to its potential for catalyzing the generation of reactive oxygen radicals in vivo.

1 April 2017 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PLPaul Loubet
Paul Loubet
NLN. Lenzi
N. Lenzi
MVM. Valette
M. Valette
VFV. Foulongne
V. Foulongne
AKA. Krivine
A. Krivine
IGI. Goderel
I. Goderel

1 January 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VRVincent Ribrag
Vincent Ribrag
JDJehan Dupuis
Jehan Dupuis
HTHerve Tilly
Herve Tilly
FMFranck Morschhauser
Franck Morschhauser
FLFabrice Laine
Fabrice Laine
BCBertrand Coiffier
Bertrand Coiffier
Purpose: To determine recommended dose, dose-limiting toxicity, safety profile, pharmacokinetics, preliminary antitumor activity, and exploratory pharmacodynamics of SAR3419, an antibody–drug conjugate targeting CD19, administered alone by intravenous infusion weekly (qw), in a dose-escalation phase I study in patients with refractory/relapsed (R/R) non-Hodgkin lymphoma (NHL). Experimental Design: Patients with R/R CD19+ B-NHL were treated with escalating doses of SAR3419 repeated qw for eight to 12 doses. On the basis of clinical evidence of late or cumulative toxicities, the study protocol was amended to test an “optimized” administration schedule consisting of four qw doses followed by four biweekly (q2w) doses (qw/q2w) at the recommended dose with the intent of reducing drug accumulation. Results: Forty-four patients were treated on seven dose levels ranging from 5 to 70 mg/m2. SAR3419 recommended dose was determined as 55 mg/m2 qw. Twenty-five patients received the qw/q2w schedule at 55 mg/m2, which showed an improved safety profile compared with the qw schedule. Antilymphoma activity was observed with both schedules in around 30% of patients with either indolent or aggressive diseases. SAR3419 displayed a long terminal half-life (approximately 7 days) and a low clearance (approximately 0.6 L/d), with no dose effect. The qw/q2w schedule allowed limiting accumulation with a decrease in SAR3419 plasma trough and average concentrations by around 1.4-fold compared with the qw schedule. Conclusion: While administered weekly, SAR3419 is well tolerated and active. The qw/q2w schedule that shows an improved safety profile and preserves antilymphoma activity is selected for clinical phase II studies. Clin Cancer Res; 20(1); 213–20. ©2013 AACR.

1 June 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
PRPr Marc Ruivard
Pr Marc Ruivard
FLFabrice Lainé
Fabrice Lainé
TGTomas Ganz
Tomas Ganz
GOGordana Olbina
Gordana Olbina
MWMark Westerman
Mark Westerman
CCCharles COUDRAY
Charles COUDRAY